Dyadic International, Inc (NASDAQ:DYAI)’s share price was up 9.5% during trading on Monday . The company traded as high as $6.74 and last traded at $6.60, approximately 249,385 shares were traded during mid-day trading. An increase of 308% from the average daily volume of 61,159 shares. The stock had previously closed at $6.03.
A number of equities analysts recently commented on DYAI shares. ValuEngine lowered Dyadic International from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Noble Financial reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Dyadic International in a research note on Monday, July 8th.
Dyadic International (NASDAQ:DYAI) last posted its quarterly earnings data on Tuesday, August 13th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.40 million. On average, research analysts predict that Dyadic International, Inc will post -0.31 EPS for the current fiscal year.
A number of hedge funds have recently modified their holdings of the business. Bank of America Corp DE bought a new stake in Dyadic International in the second quarter worth approximately $577,000. Vanguard Group Inc. bought a new stake in Dyadic International in the second quarter worth approximately $4,443,000. BlackRock Inc. bought a new stake in Dyadic International in the second quarter worth approximately $337,000. Bandera Partners LLC bought a new stake in Dyadic International in the second quarter worth approximately $9,534,000. Finally, Northern Trust Corp bought a new stake in Dyadic International in the second quarter worth approximately $218,000. Institutional investors and hedge funds own 7.88% of the company’s stock.
Dyadic International Company Profile (NASDAQ:DYAI)
Dyadic International, Inc, a biotechnology platform company, engages in the development, production, and sale of enzymes and other proteins in the United States and the Netherlands. It utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial production of human and animal vaccines, monoclonal antibodies, bi-specific antibodies, fab antibody fragments, FC-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins.
Recommended Story: What Factors Can Affect Return on Equity?
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.